Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
39,458,503
-
Shares change
-
-4,628,545
-
Total reported value, excl. options
-
$35,390,528
-
Value change
-
-$10,272,333
-
Put/Call ratio
-
246%
-
Number of buys
-
17
-
Number of sells
-
-31
-
Price
-
$0.8970
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2023
60 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q3 2023.
ADC Therapeutics SA - Common Shares (ADCT) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39,458,503 shares
of 124,058,172 outstanding shares and own 32% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (14,178,045 shares), Prosight Management, LP (5,402,041 shares), Sio Capital Management, LLC (3,294,534 shares), CITADEL ADVISORS LLC (2,898,121 shares), MILLENNIUM MANAGEMENT LLC (2,650,251 shares), Frazier Life Sciences Management, L.P. (1,647,030 shares), BANK OF AMERICA CORP /DE/ (1,533,931 shares), Affinity Asset Advisors, LLC (1,100,000 shares), AlphaCentric Advisors LLC (1,068,468 shares), and GOLDMAN SACHS GROUP INC (1,052,978 shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.